Deciphering the Prognostic and Therapeutic Value of a Gene Model Associated with Two Aggressive Hepatocellular Carcinoma Phenotypes Using Machine Learning

Overview

Journal J Hepatocell Carcinoma

Date 2024 Dec 5

PMID 39634327

Authors

Junhan Pan

Cong Zhang

Huizhen Huang

Yanyan Zhu

Yuhao Zhang

Shuzhen Wu

Yan-Ci Zhao

Feng Chen

Affiliations

Soon will be listed here.

Abstract

Background: Macrotrabecular-massive (MTM) and vessels encapsulating tumor clusters (VETC)-hepatocellular carcinoma (HCC) are aggressive histopathological phenotypes with significant prognostic implications. However, the molecular markers associated with MTM-HCC and VETC-HCC and their implications for clinical outcomes and therapeutic strategies remain unclear.

Methods: Utilizing the TCGA-LIHC cohort, we employed machine learning techniques to develop a prognostic risk score based on MTM and VETC-related genes. The performance of the risk score was assessed by investigating various aspects including clinical outcomes, biological pathways, treatment responses, drug sensitivities, tumor microenvironment, and molecular subclasses. To validate the risk score, additional data from the ICGC-JP, GSE14520, GSE104580, GSE109211, and an in-house cohort were collected and analyzed.

Results: The machine learning algorithm established a 4-gene-based risk score. High-risk patients had significantly worse prognosis compared to low-risk patients, with the risk score being associated with malignant progression of HCC. Functionally, the high-risk group exhibited enrichment in tumor proliferation pathways. Additionally, patients in the low-risk group exhibited improved response to TACE and sorafenib treatments compared to the high-risk group. In contrast, the high-risk group exhibited reduced sensitivity to immunotherapy and increased sensitivity to paclitaxel. In the in-house cohort, high-risk patients displayed higher rates of early recurrence, along with an increased frequency of elevated alpha-fetoprotein, microvascular invasion, and aggressive MRI features associated with HCC.

Conclusion: This study has successfully developed a risk score based on MTM and VETC-related genes, providing a promising tool for prognosis prediction and personalized treatment strategies in HCC patients.

References

Yang X, Yang C, Zhang S, Geng H, Zhu A, Bernards R . Precision treatment in advanced hepatocellular carcinoma. Cancer Cell. 2024; 42(2):180-197. DOI: 10.1016/j.ccell.2024.01.007. View

Chiang D, Villanueva A, Hoshida Y, Peix J, Newell P, Minguez B . Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res. 2008; 68(16):6779-88. PMC: 2587454. DOI: 10.1158/0008-5472.CAN-08-0742. View

Calderaro J, Ziol M, Paradis V, Zucman-Rossi J . Molecular and histological correlations in liver cancer. J Hepatol. 2019; 71(3):616-630. DOI: 10.1016/j.jhep.2019.06.001. View

Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X . Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018; 24(10):1550-1558. PMC: 6487502. DOI: 10.1038/s41591-018-0136-1. View

Hoshida Y, Nijman S, Kobayashi M, Chan J, Brunet J, Chiang D . Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 2009; 69(18):7385-92. PMC: 3549578. DOI: 10.1158/0008-5472.CAN-09-1089. View

Liu J, Lichtenberg T, Hoadley K, Poisson L, Lazar A, Cherniack A . An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell. 2018; 173(2):400-416.e11. PMC: 6066282. DOI: 10.1016/j.cell.2018.02.052. View

Luo J, Si Z, Li T, Li J, Zhang Z, Chen G . MicroRNA-146a-5p enhances radiosensitivity in hepatocellular carcinoma through replication protein A3-induced activation of the DNA repair pathway. Am J Physiol Cell Physiol. 2018; 316(3):C299-C311. DOI: 10.1152/ajpcell.00189.2018. View

Yu B, Zhu N, Fan Z, Li J, Kang Y, Liu B . miR-29c inhibits metastasis of gastric cancer cells by targeting VEGFA. J Cancer. 2022; 13(14):3566-3574. PMC: 9723994. DOI: 10.7150/jca.77727. View

Xu X, Xing H, Han J, Li Z, Lau W, Zhou Y . Risk Factors, Patterns, and Outcomes of Late Recurrence After Liver Resection for Hepatocellular Carcinoma: A Multicenter Study From China. JAMA Surg. 2018; 154(3):209-217. PMC: 6439634. DOI: 10.1001/jamasurg.2018.4334. View

10.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

11.

Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

12.

Gillmore R, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, Burroughs A . EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol. 2011; 55(6):1309-16. DOI: 10.1016/j.jhep.2011.03.007. View

13.

Zhang Q, Lu S, Li T, Yu L, Zhang Y, Zeng H . ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa/VEGFR2/ERK pathway. J Exp Clin Cancer Res. 2019; 38(1):173. PMC: 6482513. DOI: 10.1186/s13046-019-1156-5. View

14.

Mounir M, Lucchetta M, C Silva T, Olsen C, Bontempi G, Chen X . New functionalities in the TCGAbiolinks package for the study and integration of cancer data from GDC and GTEx. PLoS Comput Biol. 2019; 15(3):e1006701. PMC: 6420023. DOI: 10.1371/journal.pcbi.1006701. View

15.

Nagtegaal I, Odze R, Klimstra D, Paradis V, Rugge M, Schirmacher P . The 2019 WHO classification of tumours of the digestive system. Histopathology. 2019; 76(2):182-188. PMC: 7003895. DOI: 10.1111/his.13975. View

16.

Zhang P, Ono A, Fujii Y, Hayes C, Tamura Y, Miura R . The presence of vessels encapsulating tumor clusters is associated with an immunosuppressive tumor microenvironment in hepatocellular carcinoma. Int J Cancer. 2022; 151(12):2278-2290. DOI: 10.1002/ijc.34247. View

17.

Fang J, Zhou H, Zhang C, Shang L, Zhang L, Xu J . A novel vascular pattern promotes metastasis of hepatocellular carcinoma in an epithelial-mesenchymal transition-independent manner. Hepatology. 2015; 62(2):452-65. DOI: 10.1002/hep.27760. View

18.

Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S . Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg. 2014; 261(5):947-55. DOI: 10.1097/SLA.0000000000000710. View

19.

Kurebayashi Y, Matsuda K, Ueno A, Tsujikawa H, Yamazaki K, Masugi Y . Immunovascular classification of HCC reflects reciprocal interaction between immune and angiogenic tumor microenvironments. Hepatology. 2021; 75(5):1139-1153. DOI: 10.1002/hep.32201. View

20.

Wei H, Fu F, Jiang H, Wu Y, Qin Y, Wei H . Development and validation of the OSASH score to predict overall survival of hepatocellular carcinoma after surgical resection: a dual-institutional study. Eur Radiol. 2023; 33(11):7631-7645. PMC: 10598081. DOI: 10.1007/s00330-023-09725-7. View